AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
ApexOnco Front Page
Recent articles
A son of glembatumumab vedotin has just started its phase 1 study.
After a delay, the Alpha-3 study faces an April futility analysis.
A first-in-human trial of PRT12396 starts next month.
Early data are coming with the KRAS G12D degrader ARV-806.
Pivotal trials of sonrotoclax plus the group’s BTK degrader are set to start soon.
Clinical trial entrants include projects from Gyala, Beijing Biotech and Neowise.
After reporting stellar data at ASH, Terns is acquired for $6.7bn.
